Search All News
Diana Martinez discusses the interaction between cannabis and psychiatric disorders.
"[Buprenorphine] is a tremendously powerful medication, saves many lives and prevents overdose, but there is a risk of misuse and diversion, albeit pretty low," says Dr. Francis Levin.
- April 15, 2019
Columbia Psychiatrists suggest that researchers, pharmaceutical companies, and the FDA reconsider placebo-controlled, relapse prevention studies in schizophrenia.
Source:JAMAApril 10, 2019
Dr. Jeffrey Lieberman and colleagues conclude that the time has come to cease the use of placebo in relapse prevention studies and encourage the use of active comparators.
Source:MD MagazineMarch 8, 2019
Dr. Jeffrey Lieberman’s concerns about whether dosing strategies for ketamine have been properly set by clinical trials are mentioned in this Q&A.
Source:NewsDayFebruary 23, 2019
Schizophrenia and other psychotic disorders affect each person differently and vary in severity, said Dr. Lisa Dixon.
Source:HealioFebruary 21, 2019
“The effectiveness of combinations of antipsychotic medications remains unclear; reviews of this treatment strategy agree on the need for further investigation,” Dr. T. Scott Stroup and team wrote.
- February 20, 2019
Patients with schizophrenia are often treated with more than one type of psychiatric medication, but a new study suggests that some combinations may be more effective than others.
Source:HealioFebruary 20, 2019
Dr. J. John Mann writes that ketamine “has a fairly robust effect on reducing suicidal ideation.”
- February 8, 2019
The Columbia Ketamine program offers innovative and responsible care for treatment-resistant depression.
Source:Bloomberg NewsFebruary 5, 2019
“Most people inhibit suicide. They find a reason not to do it,” Dr. Mark Underwood says.